37661 |
Oncology |
Biomarker-driven phase 2 umbrella trial study for patients with recurr... |
CANCER 2020 10.1002/cncr.33048 |
정현애 |
2020 |
37660 |
Oncology; Clinical Neurology |
Diagnostic accuracy of MR imaging of patients with leptomeningeal seed... |
J NEURO-ONCOL 2020 10.1007/s11060-020-03617-2 |
박세훈A |
2020 |
37659 |
Oncology |
Osimertinib in central nervous system progressive EGFR-mutant lung can... |
ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234 |
박세훈A |
2020 |
37658 |
Oncology |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell L... |
CANCER RES TREAT 2020 10.4143/crt.2020.278 |
박세훈A |
2020 |
37657 |
Oncology; Cell Biology |
Clinical Characteristics and Exploratory Genomic Analyses of Germline ... |
MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108 |
박세훈A |
2020 |
37656 |
Oncology |
Biomarker-driven phase 2 umbrella trial study for patients with recurr... |
CANCER 2020 10.1002/cncr.33048 |
박세훈A |
2020 |
37655 |
Oncology |
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGF... |
ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 |
박세훈A |
2020 |
37654 |
Biology |
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harbor... |
BIOLOGY-BASEL 2020 10.3390/biology9100326 |
박세훈A |
2020 |
37653 |
Oncology; Respiratory System |
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NS... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 |
박세훈A |
2020 |
37652 |
Pharmacology & Pharmacy |
Evaluating entrectinib as a treatment option for non-small cell lung c... |
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 |
박세훈A |
2020 |